All In Biotech

Drug Trial Radar · NCT07778693

Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 760 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

760

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Sep 2027

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity. Approximately 760 participants will be enrolled. All participants will be stratified by gender (male or female) and baseline BMI level, and then randomized 1:1:1:1 to 4 treatment groups, with 190 participants per group. All treatment groups will implement dose titration to achieve the target dose. The study comprises a screening period of up to 2 weeks, a 52-week treatment period, and a 4-week follow-up period, for a total study duration of 58 weeks. The primary endpoints are the percentage change in body weight from baseline and the proportion of participants achieving ≥5% weight reduction from baseline at Week 52. The secondary endpoints include the proportions of participants achieving ≥10% and ≥15% weight reduction from baseline, as well as the change from baseline in waist circumference at Week 52.

Conditions

  • Overweight , Obesity

Interventions

  • MWN109 1Drug

    Administered SC, QW, 52 weeks

  • MWN109 2Drug

    Administered SC, QW, 52 weeks

  • MWN109 3Drug

    Administered SC, QW, 52 weeks

  • PlaceboDrug

    Administered SC, QW, 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change from Baseline in Body Weight at Week 52Time frame: Baseline, Week 52
  2. Proportion of Participants Achieving ≥5% Body Weight Reduction from Baseline at Week 52Time frame: Baseline, Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.